Commercialization of an siRNA business for KRAS-mutant cancers through a US-based drug discovery company
An initiative to obtain FDA approval for an siRNA formulation for KRAS-mutant cancers and advance it into Phase I clinical trials through a US-based company focused exclusively on drug discovery, thereby promoting commercialization.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.